Search - tctmd.com

Displaying 781 - 800 of 868

Sort: Relevancy | Date

Presentation TCT 2012

Dedicated Bifurcation Stents: Cappella Program Update

Presenter: Fernando Cura

October 22, 2012

Presentation TCT 2012

Dedicated Bifurcation Stents: Biosensors Program Update

Presenter: Stefan Verheye

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Presenter: Gary Ansel

October 22, 2012

Presentation TCT 2012

Bioabsorbable Stents

Presenter: Hector Garcia-Garcia

October 22, 2012

Presentation TCT 2012

Are the Outcomes of Left Main Stenting Improving with Second Generation Stents? Results of PRECOMBAT-2

Presenter: Young-Hak Kim

October 22, 2012

Presentation TCT 2012

When Are Two Stents Not Needed for the Distal Left Main Bifurcation?

Presenter: David Hildick-Smith

October 22, 2012

Presentation TCT 2012

The Data Are Clear: The Careful Operator Should Implant Two Stents in No More Than 10% of Bifurcation Lesions!

Presenter: Liliana Grinfeld

October 22, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 22, 2012

News Conference News TCT 2012

New Results from SYNTAX, SPIRIT Trials Presented

October 22, 2012

News Conference News TCT 2012

Meta-Analyses Show Improved Outcomes with DES vs. BMS

October 22, 2012

Presentation TCT 2012

J-DESSERT: A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents in Patients with and without Diabetes

Presenter: Masato Nakamura

October 22, 2012

Presentation TCT 2012

Final Data on the ICARUS Trial of Covered Stents for Obstructive Iliac Disease

Presenter: John Laird Jr

October 22, 2012

Presentation TCT 2012

Dedicated Bifurcation Stents: Xience SBA Program Update

Presenter: David Rizik

October 22, 2012

Presentation TCT 2012

Dedicated Bifurcation Stents: STENTYS Program Update

Presenter: Stefan Verheye

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Presenter: Lawrence Garcia

October 22, 2012

News Conference News TCT 2012

COURAGE, FAME: Revascularization More Effective Than OMT

October 22, 2012

Presentation TCT 2012

ACE-CTO: Angiographic Follow-up After Everolimus-eluting Stents in CTO

Presenter: Emmanouil Brilakis

October 22, 2012

Presentation TCT 2012

Use Of Paclitaxel-Eluting Stents Reduces Target Lesion Revascularization for Dialysis Patients.

Presenter: Hirotoshi Watanabe, Kyohei Yamaji, Yoshimitsu Soga, Shinichi Shirai, Kenji Ando, Koyu Sakai, Katsuhiro Kondo, Masashi Iwabuchi, Hiroyoshi Yokoi, Hideyuki Nosaka, Masakiyo Nobuyoshi

January 03, 2012

Presentation TCT 2012

Two-Year Outcomes of a Propensity-Matched Comparison of the ION and TAXUS Liberté Paclitaxel-Eluting Stents.

Presenter: Dean J. Kereiakes, Louis A. Cannon, John A. Ormiston, Hong Wang, Paul L. Underwood, Keith D. Dawkins

January 03, 2012

Advertisement

Dedicated Bifurcation Stents: Cappella Program Update

Dedicated Bifurcation Stents: Biosensors Program Update

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Bioabsorbable Stents

Are the Outcomes of Left Main Stenting Improving with Second Generation Stents? Results of PRECOMBAT-2

When Are Two Stents Not Needed for the Distal Left Main Bifurcation?

The Data Are Clear: The Careful Operator Should Implant Two Stents in No More Than 10% of Bifurcation Lesions!

Several Trials Highlight DES Comparisons

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

New Results from SYNTAX, SPIRIT Trials Presented

Meta-Analyses Show Improved Outcomes with DES vs. BMS

J-DESSERT: A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents in Patients with and without Diabetes

Final Data on the ICARUS Trial of Covered Stents for Obstructive Iliac Disease

Dedicated Bifurcation Stents: Xience SBA Program Update

Dedicated Bifurcation Stents: STENTYS Program Update

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

COURAGE, FAME: Revascularization More Effective Than OMT

ACE-CTO: Angiographic Follow-up After Everolimus-eluting Stents in CTO

Use Of Paclitaxel-Eluting Stents Reduces Target Lesion Revascularization for Dialysis Patients.

Two-Year Outcomes of a Propensity-Matched Comparison of the ION and TAXUS Liberté Paclitaxel-Eluting Stents.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content